US20160340414A1 - Rsv-specific antibodies and functional parts thereof - Google Patents

Rsv-specific antibodies and functional parts thereof Download PDF

Info

Publication number
US20160340414A1
US20160340414A1 US15/111,610 US201515111610A US2016340414A1 US 20160340414 A1 US20160340414 A1 US 20160340414A1 US 201515111610 A US201515111610 A US 201515111610A US 2016340414 A1 US2016340414 A1 US 2016340414A1
Authority
US
United States
Prior art keywords
seq
sequence
variable region
chain variable
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/111,610
Other languages
English (en)
Inventor
Nancy Ulbrandt
Nicole Kallewaard-LeLay
Andy Q. Yuan
Bettina Richter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Priority to US15/111,610 priority Critical patent/US20160340414A1/en
Assigned to MEDIMMUNE, LLC reassignment MEDIMMUNE, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KALLEWAARD-LELAY, Nicole, ULBRANDT, NANCY, YUAN, Andy Q., RICHTER, BETTINA
Publication of US20160340414A1 publication Critical patent/US20160340414A1/en
Assigned to MEDIMMUNE LIMITED reassignment MEDIMMUNE LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MEDIMMUNE, LLC
Assigned to MEDIMMUNE LIMITED reassignment MEDIMMUNE LIMITED ASSIGNEE CHANGE OF ADDRESS Assignors: MEDIMMUNE LIMITED
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C07K16/1027—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Definitions

  • the antibody or functional part comprises a heavy chain sequence variable region comprising a sequence which is at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the framework (i.e., non CDR) sequence of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 21.
  • the framework i.e., non CDR sequence of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 21.
  • the antibody or functional part may comprise at least one of the alternative heavy chain CDRs from Table 14 and may have at least one other CDR modification.
  • the antibody or functional part may comprise a heavy chain CDR1 sequence comprising a sequence which differs by one amino acid from NYIIN (SEQ ID NO: 1)
  • a heavy chain CDR2 sequence comprises a sequence which differs by one or two amino acids from GIIPVLGTVHYAPKFQG (SEQ ID NO: 2)
  • a heavy chain CDR3 sequence comprises a sequence which differs by one or two amino acid from ETALVVSTTYLPHYFDN (SEQ ID NO: 3)
  • a light chain CDR1 sequence comprises a sequence which differs by one amino acid from QASQDIVNYLN (SEQ ID NO: 4)
  • a light chain CDR2 sequence comprises a sequence which differs by one amino acid from VASNLET (SEQ ID NO: 5)
  • a light chain CDR3 sequence comprises a sequence which differs by one amino acid from

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US15/111,610 2014-01-15 2015-01-14 Rsv-specific antibodies and functional parts thereof Abandoned US20160340414A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/111,610 US20160340414A1 (en) 2014-01-15 2015-01-14 Rsv-specific antibodies and functional parts thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461927819P 2014-01-15 2014-01-15
PCT/US2015/011391 WO2015108967A2 (en) 2014-01-15 2015-01-14 Rsv-specific antibodies and functional parts thereof
US15/111,610 US20160340414A1 (en) 2014-01-15 2015-01-14 Rsv-specific antibodies and functional parts thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/011391 A-371-Of-International WO2015108967A2 (en) 2014-01-15 2015-01-14 Rsv-specific antibodies and functional parts thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/003,455 Continuation US10689437B2 (en) 2014-01-15 2018-06-08 RSV-specific antibodies and functional parts thereof

Publications (1)

Publication Number Publication Date
US20160340414A1 true US20160340414A1 (en) 2016-11-24

Family

ID=53543612

Family Applications (6)

Application Number Title Priority Date Filing Date
US15/111,610 Abandoned US20160340414A1 (en) 2014-01-15 2015-01-14 Rsv-specific antibodies and functional parts thereof
US16/003,455 Active US10689437B2 (en) 2014-01-15 2018-06-08 RSV-specific antibodies and functional parts thereof
US16/864,454 Active US11186628B2 (en) 2014-01-15 2020-05-01 RSV-specific antibodies and functional parts thereof
US17/451,955 Active US11661449B2 (en) 2014-01-15 2021-10-22 RSV-specific antibodies and functional parts thereof
US18/302,400 Active US12173050B2 (en) 2014-01-15 2023-04-18 RSV-specific antibodies and functional parts thereof
US18/943,007 Pending US20250179153A1 (en) 2014-01-15 2024-11-11 Rsv-specific antibodies and functional parts thereof

Family Applications After (5)

Application Number Title Priority Date Filing Date
US16/003,455 Active US10689437B2 (en) 2014-01-15 2018-06-08 RSV-specific antibodies and functional parts thereof
US16/864,454 Active US11186628B2 (en) 2014-01-15 2020-05-01 RSV-specific antibodies and functional parts thereof
US17/451,955 Active US11661449B2 (en) 2014-01-15 2021-10-22 RSV-specific antibodies and functional parts thereof
US18/302,400 Active US12173050B2 (en) 2014-01-15 2023-04-18 RSV-specific antibodies and functional parts thereof
US18/943,007 Pending US20250179153A1 (en) 2014-01-15 2024-11-11 Rsv-specific antibodies and functional parts thereof

Country Status (26)

Country Link
US (6) US20160340414A1 (https=)
EP (3) EP3741390A1 (https=)
JP (4) JP6836398B2 (https=)
KR (1) KR102188437B1 (https=)
CN (2) CN116355080A (https=)
AU (4) AU2015206570A1 (https=)
CA (1) CA2933200C (https=)
CY (2) CY1123425T1 (https=)
DK (1) DK3094353T3 (https=)
ES (1) ES2795727T3 (https=)
FI (1) FIC20230016I1 (https=)
FR (1) FR23C1016I1 (https=)
HR (1) HRP20200607T1 (https=)
HU (2) HUE048855T2 (https=)
LT (2) LT3094353T (https=)
LU (1) LUC00305I2 (https=)
MX (1) MX374517B (https=)
NL (1) NL301228I2 (https=)
NO (1) NO2023016I1 (https=)
PL (1) PL3094353T3 (https=)
PT (1) PT3094353T (https=)
RS (1) RS60387B1 (https=)
SI (1) SI3094353T1 (https=)
SM (1) SMT202000282T1 (https=)
TW (1) TWI705974B (https=)
WO (1) WO2015108967A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059757B2 (en) 2007-06-01 2018-08-28 Medimmune Limited RSV-specific binding molecules and means for producing them
WO2019152600A1 (en) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Nucleic acid antibody constructs for use against respiratory syncytial virus
US10689437B2 (en) 2014-01-15 2020-06-23 Medimmune, Llc RSV-specific antibodies and functional parts thereof
US10774133B2 (en) 2017-03-01 2020-09-15 Medimmune Limited Anti-RSV monoclonal antibody formulation
US12024553B2 (en) 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
US12617841B2 (en) * 2019-01-31 2026-05-05 The Wistar Institute Of Anatomy And Biology Nucleic acid antibody constructs for use against respiratory syncytial virus

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
CN111606993B (zh) * 2019-02-26 2022-06-28 中国科学院上海生命科学研究院 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
CA3229901A1 (en) 2021-09-13 2023-03-16 Medimmune Limited Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab
CN119264248A (zh) * 2022-07-22 2025-01-07 北京智仁美博生物科技有限公司 抗呼吸道合胞病毒中和性抗体及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO2006050166A2 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
AU2005335714B2 (en) * 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
MX2009003306A (es) 2006-10-02 2009-04-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y sus usos.
JP2010534057A (ja) * 2007-03-06 2010-11-04 シムフォゲン・アクティーゼルスカブ 呼吸器合胞体ウイルス感染症を治療するための組換え抗体
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20110008329A1 (en) * 2007-06-26 2011-01-13 Medlmmune, Llc Methods of Treating RSV Infections And Related Conditions
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
TWI478937B (zh) 2008-01-15 2015-04-01 Abbvie Inc 改良之哺乳動物表現載體及其用途
US9273118B2 (en) * 2009-07-15 2016-03-01 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
JP5762408B2 (ja) * 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP2486053B1 (en) * 2009-10-06 2017-01-18 Medimmune Limited Rsv-specific binding molecule
US20120263715A1 (en) 2009-10-28 2012-10-18 Medimmune, Llc Topical Methods Of Treating RSV Infections And Related Conditions
BR112012031638B1 (pt) * 2010-07-09 2021-01-12 Janssen Vaccines & Prevention B.V. anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado
CA2867444C (en) * 2012-03-16 2021-04-13 University Health Network Compositions containing soluble toso protein and uses thereof
US20150158942A1 (en) * 2012-05-22 2015-06-11 Shire Human Genetic Therapies, Inc. Anti-ccl2 antibodies for treatment of scleroderma
CA2900110A1 (en) 2013-02-01 2014-08-07 Medimmune, Llc Respiratory syncytial virus f protein epitopes
ES2795727T3 (es) * 2014-01-15 2020-11-24 Medimmune Llc Anticuerpos específicos del vrs y partes funcionales de los mismos
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10730931B2 (en) 2007-06-01 2020-08-04 Medimmune Limited RSV-specific binding molecules and means for producing them
US10059757B2 (en) 2007-06-01 2018-08-28 Medimmune Limited RSV-specific binding molecules and means for producing them
US11661449B2 (en) 2014-01-15 2023-05-30 Medimmune Limited RSV-specific antibodies and functional parts thereof
US10689437B2 (en) 2014-01-15 2020-06-23 Medimmune, Llc RSV-specific antibodies and functional parts thereof
US11186628B2 (en) 2014-01-15 2021-11-30 Medimmune, Llc RSV-specific antibodies and functional parts thereof
US12173050B2 (en) 2014-01-15 2024-12-24 Medimmune Limited RSV-specific antibodies and functional parts thereof
US10774133B2 (en) 2017-03-01 2020-09-15 Medimmune Limited Anti-RSV monoclonal antibody formulation
US11286294B2 (en) 2017-03-01 2022-03-29 Medimmune Limited Anti-RSV monoclonal antibody formulation
US11667698B2 (en) 2017-03-01 2023-06-06 Medimmune Limited Anti-RSV monoclonal antibody formulation
CN111936513A (zh) * 2018-01-31 2020-11-13 威斯塔解剖学和生物学研究所 用于抗呼吸道合胞病毒的核酸抗体构筑体
US20210047390A1 (en) * 2018-01-31 2021-02-18 The Wistar Institute Of Anatomy And Biology Nucleic acid antibody constructs for use against respiratory syncytial virus
WO2019152600A1 (en) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Nucleic acid antibody constructs for use against respiratory syncytial virus
US12617841B2 (en) * 2019-01-31 2026-05-05 The Wistar Institute Of Anatomy And Biology Nucleic acid antibody constructs for use against respiratory syncytial virus
US12024553B2 (en) 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies

Also Published As

Publication number Publication date
EP3094353A4 (en) 2017-09-06
NO2023016I1 (no) 2023-04-25
CY2023011I1 (el) 2023-11-15
JP2025063143A (ja) 2025-04-15
US11661449B2 (en) 2023-05-30
US12173050B2 (en) 2024-12-24
CN116355080A (zh) 2023-06-30
ES2795727T3 (es) 2020-11-24
MX374517B (es) 2025-03-06
US20220098285A1 (en) 2022-03-31
PT3094353T (pt) 2020-06-08
WO2015108967A3 (en) 2015-09-03
CA2933200A1 (en) 2015-07-23
US20250179153A1 (en) 2025-06-05
FR23C1016I1 (fr) 2023-06-23
AU2015206570A1 (en) 2016-07-14
HK1225992A1 (en) 2017-09-22
TWI705974B (zh) 2020-10-01
AU2021204339B2 (en) 2024-11-14
LUC00305I2 (https=) 2025-09-22
CY2023011I2 (el) 2023-11-15
EP3094353A2 (en) 2016-11-23
AU2020203831A1 (en) 2020-07-02
CA2933200C (en) 2025-05-06
EP3741390A1 (en) 2020-11-25
CY1123425T1 (el) 2021-12-31
FIC20230016I1 (fi) 2023-04-26
RS60387B1 (sr) 2020-07-31
US20190106482A1 (en) 2019-04-11
EP3094353B1 (en) 2020-04-01
BR112016015044A2 (pt) 2017-09-19
SMT202000282T1 (it) 2020-07-08
JP2017504321A (ja) 2017-02-09
JP2020103293A (ja) 2020-07-09
HRP20200607T1 (hr) 2020-07-10
ES2795727T9 (en) 2026-01-21
PL3094353T3 (pl) 2020-09-07
BR112016015044A8 (pt) 2023-04-11
HUE048855T2 (hu) 2020-08-28
AU2025201056A1 (en) 2025-03-06
JP2023052693A (ja) 2023-04-11
NL301228I1 (https=) 2023-05-03
LT3094353T (lt) 2020-08-10
HUS2300019I1 (hu) 2023-05-28
EP4353316A2 (en) 2024-04-17
WO2015108967A2 (en) 2015-07-23
AU2021204339A1 (en) 2021-07-22
WO2015108967A8 (en) 2015-10-01
MX2016008639A (es) 2017-02-15
TW201612191A (en) 2016-04-01
RU2016133247A3 (https=) 2019-01-16
SI3094353T1 (sl) 2020-07-31
DK3094353T3 (da) 2020-06-02
EP4353316A3 (en) 2024-08-21
JP6836398B2 (ja) 2021-03-03
LTC3094353I2 (https=) 2025-07-10
US11186628B2 (en) 2021-11-30
NL301228I2 (nl) 2023-09-13
CN105916520A (zh) 2016-08-31
RU2016133247A (ru) 2018-02-20
KR102188437B1 (ko) 2020-12-08
LTPA2023514I1 (https=) 2023-05-25
KR20160104018A (ko) 2016-09-02
US20230365660A1 (en) 2023-11-16
US10689437B2 (en) 2020-06-23
US20200331989A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
US12173050B2 (en) RSV-specific antibodies and functional parts thereof
US8124092B2 (en) Antibodies against H5N1 strains of influenza A virus
WO2017092645A1 (zh) 一种抗呼吸道合胞病毒的全人源抗体
JP2024522670A (ja) 呼吸器合胞体ウイルスに対する抗体及びその使用
JP6538151B2 (ja) 抗ｃ型肝炎抗体及びその抗原結合断片
HK40109087A (en) Rsv-specific antibodies and functional parts thereof
HK40041855A (en) Rsv-specific antibodies and functional parts thereof
RU2785598C2 (ru) Rsv-специфичные антитела и их функциональные части
HK1225992B (en) Rsv-specific antibodies and functional parts thereof
BR112016015044B1 (pt) Anticorpos específicos para rsv e partes funcionais dos mesmos
US20250382354A1 (en) Cross-specific antibodies, uses and methods for discovery thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: MEDIMMUNE, LLC, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ULBRANDT, NANCY;KALLEWAARD-LELAY, NICOLE;YUAN, ANDY Q.;AND OTHERS;SIGNING DATES FROM 20150603 TO 20150611;REEL/FRAME:039555/0631

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: MEDIMMUNE LIMITED, GREAT BRITAIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDIMMUNE, LLC;REEL/FRAME:059346/0018

Effective date: 20220216

AS Assignment

Owner name: MEDIMMUNE LIMITED, UNITED KINGDOM

Free format text: ASSIGNEE CHANGE OF ADDRESS;ASSIGNOR:MEDIMMUNE LIMITED;REEL/FRAME:063350/0476

Effective date: 20230417